Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26817694 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2C19CYP2D6CYP3A4 | |
| SCHEMBL19936695 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP2C19CYP2D6CYP3A4 | |
| SCHEMBL22995523 | 0.98 | ALDH1A1 (0.39) | ALDH1A1TSHRCYP2C19CYP2D6CYP3A4 | |
| SCHEMBL15468146 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL3L3MBTL1HTR6 | |
| SCHEMBL14355437 | 0.87 | — | — | |
| Water SCHEMBL27993515 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL3L3MBTL1HTR6 | |
| Iodide SCHEMBL28815625 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL3L3MBTL1HTR6 | |
| SCHEMBL12226752 | 0.86 | HTR6 (0.41) | ALDH1A1TSHRCYP2D6HTR6 | |
| SCHEMBL16566607 | 0.86 | ALDH1A1 (0.49) | ALDH1A1TSHRCYP2D6L3MBTL3L3MBTL1 | |
| SCHEMBL24700391 | 0.86 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP2C19CYP3A4L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | ALDH1A1 722/4885TSHR 3891/4885CYP2C19 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.